Cheyne Capital Management (UK)’s Iovance Biotherapeutics IOVA Stock Holding History

Cheyne Capital Management (UK)’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-25,000	Closed	-$651K	–	116
2021 Q2	$651K	Buy	+25,000	New	+$650K	0.3%	59
2020 Q4	–	Sell	-17,250	Closed	-$568K	–	95
2020 Q3	$568K	Buy	+17,250	New	+$529K	0.28%	51
2020 Q1	–	Sell	-80,000	Closed	-$2.21M	–	46
2019 Q4	$2.21M	Sell	80,000 -71,500	-47%	-$1.63M	1.34%	32
2019 Q3	$2.76M	Sell	151,500 -35,000	-19%	-$774K	1.74%	27
2019 Q2	$4.57M	Hold	186,500	–	–	3.32%	11
2019 Q1	$1.77M	Hold	186,500	–	–	1.66%	26
2018 Q4	$1.65M	Sell	186,500 -13,500	-7%	-$130K	1.56%	24
2018 Q3	$2.25M	Buy	+200,000	New	+$2.84M	1.34%	31

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Cheyne Capital Management (UK)'s IOVA Position: Q3 2021 in Review

Cheyne Capital Management (UK) sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 25,000 shares — an estimated $651K sold.

Cheyne Capital Management (UK) first reported a position in IOVA in Q3 2018 and held it in 8 quarters. The position peaked at $4.57M in Q2 2019. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

Cheyne Capital Management (UK) reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
Cheyne Capital Management (UK) sold 25,000 Iovance Biotherapeutics shares in Q3 2021, an estimated $651K.
Cheyne Capital Management (UK) first reported a position in Iovance Biotherapeutics in Q3 2018 and held it in 8 quarters.
Cheyne Capital Management (UK)'s Iovance Biotherapeutics position peaked at $4.57M in Q2 2019.
243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Cheyne Capital Management (UK)'s 13F filing for Q3 2021, filed 12 Nov 2021.